迈威生物：与CALICO拟就IL-11靶向治疗（包括9MW3811）签署独家许可协议

Core Viewpoint - Maiwei Biotech has signed an exclusive licensing agreement with CALICO for IL-11 targeted therapy, including 9MW3811, allowing CALICO to develop, produce, and commercialize the product outside Greater China [1] Group 1: Licensing Agreement Details - The agreement grants Maiwei Biotech exclusive rights to license CALICO for the development, production, and commercialization of the product in all regions except Greater China (Mainland China, Hong Kong, Macau, and Taiwan) [1] - Maiwei Biotech will receive an upfront payment and milestone payments, as well as tiered royalties based on net sales of the licensed product [1] Group 2: Product Information - 9MW3811 is a humanized monoclonal antibody developed by Maiwei Biotech that effectively blocks the activation of IL-11 downstream signaling pathways, aiming to treat fibrosis and tumors [1] - The product has received approval for clinical trials in China, Australia, and the United States, with Phase I clinical studies completed in China and Australia [1] Group 3: Financial Aspects - CALICO will pay an upfront non-refundable payment of $25 million to Maiwei Biotech [1] - Additionally, Maiwei Biotech could receive up to $571 million in potential milestone payments related to near-term, development, registration, and commercialization, along with tiered royalties based on net sales of the licensed product [1]